Comparison of Remimazolam versus Sevoflurane on the Postoperative Quality of Recovery in Cervical Spine Surgery: A Prospective Randomized Controlled Double-Blind Trial
Jiwon Lee,Dong Woo Han,Na Young Kim,Keun-Su Kim,Yunil Yang,Juyeon Yang,Hye Sun Lee,Myoung Hwa Kim
DOI: https://doi.org/10.2147/dddt.s441622
IF: 4.3188
2024-01-24
Drug Design Development and Therapy
Abstract:Jiwon Lee, 1 Dong Woo Han, 1 Na Young Kim, 2 Keun-Su Kim, 3 Yunil Yang, 1 Juyeon Yang, 4 Hye Sun Lee, 4 Myoung Hwa Kim 1 1 Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Republic of Korea; 2 Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea; 3 Department of Neurosurgery, Spine and Spinal Cord Institute, Gangnam Severance Spine Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; 4 Department of Research Affairs, Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Republic of Korea Correspondence: Myoung Hwa Kim, Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Republic of Korea, Fax +82-2-3463-0940, Email Purpose: Remimazolam is a newly developed ultra-short-acting benzodiazepine. We compared overall functional recovery, including the postoperative Quality of Recovery-15 (QoR-15) questionnaire scores, between balanced inhalational anesthesia using sevoflurane and total intravenous anesthesia (TIVA) with remimazolam in patients undergoing anterior cervical discectomy and fusion (ACDF). Patients and Methods: Seventy-two patients were randomized to the remimazolam (group R) or sevoflurane (group S) group. The primary outcome was the total QoR-15 score on postoperative day (POD) 1. We also assessed the total QoR-15 score on POD2, sub-scores of the QoR-15, perioperative parameters, and postoperative recovery profiles. Group-time interaction effects on the QoR-15 and its sub-scores were analyzed using a linear mixed model. Results: The total QoR-15 score on POD1 (120.2 in group R vs 114.3 in group S, P =0.189) was not statistically different between the groups. There were no significant group-time interaction effects on total QoR-15 scores. Instead, patients in group R showed significantly better sub-scores in psychological and postoperative nausea and vomiting (PONV) items on POD1, as well as a lower degree of PONV, than those in group S. Among the five dimensions of the QoR-15, a significant group-time interaction effect was observed for psychological support. Group R showed significantly less changeability in blood pressure and heart rate with a lower dose of intraoperatively administered vasopressor than group S. Conclusion: Considering QoR-15, including PONV reduction, and intraoperative hemodynamic stability, remimazolam can be used as the novel and safe anesthetic agent for maintaining general anesthesia instead of sevoflurane in patients undergoing ACDF. Plain Language Summary: Compared with balanced anesthesia using sevoflurane, total intravenous anesthesia with remimazolam showed better aspects for psychological support and postoperative nausea/vomiting in the quality of recovery and hemodynamic stability. Despite comparable total Quality of Recovery-15 scores, remimazolam-based total intravenous anesthesia could be a secure and suitable choice for patients undergoing cervical spine surgery. Keywords: cervical spine surgery, quality of recovery, remimazolam, sevoflurane, total intravenous anesthesia Remimazolam is a sedative of the benzodiazepine class‒an ester-based gamma-aminobutyric acid type A (GABA A ) receptor agonist. It has several distinct advantages over existing benzodiazepines, including rapid onset, a short context-sensitive half-time, being metabolized by tissue esterase independent of hepatic or renal function, producing an inactive metabolite, existence of an antidote (antagonized by flumazenil), and hemodynamic stability. 1–7 Remimazolam was recently developed and is safe even with continuous intravenous infusion; as a result, it has been gradually used as an anesthetic for sedation or general anesthesia. 5,8 However, there is a lack of studies clarifying the postoperative functional recovery of patients after remimazolam administration, especially compared with that of balanced inhalational anesthesia. Moreover, if the quality of postoperative recovery is low, the actual length of stay in hospital or the medical cost increases, further affecting the long-term prognosis as well as lowering patient satisfaction. 9–11 Accordingly, anesthesiologists must consider hypnotic agents and anesthetic methods that provide fast and high-quality recovery, minimizing perioperative morbidities and the time taken to resume daily activities. The Quali -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal